RNA Editing Signatures Predict Response to Immunotherapies in Melanoma Patients
Siddiqui, J. K.; Miles, W. O.
Show abstract
Summary ParagraphImmunotherapy has improved the prognosis for half of the melanoma patients, prompting a need to understand differences between responding and non-responding patients. Gene expression profiling of tumors has focused on deriving primarily immune-related signatures, however these have shown limited predictive power. Recent studies have highlighted the role of RNA editing in modulating resistance to immunotherapy. This has led us to test whether RNA editing activity can be predictive of response in publicly available datasets of immunotherapy-treated melanoma patients. Here, we identified RNA editing signatures that were able to predict with very high accuracy and confidence patient responses and outcomes. Our analysis, however, demonstrates that RNA editing by itself is sufficient as a strong predictive tool for examining sensitivity of melanoma patients to immunotherapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Predicting tumor immune microenvironment and checkpoint therapy response of head & neck cancer patients from blood immune single-cell transcriptomics 94%
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 94%
- SpliceMutr enables pan-cancer analysis of splicing-derived neoantigen burden in tumors 93%
Similar papers in this journal
- Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma 96%
- Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy 93%
- Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes 93%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 94%
- Single-cell profiling of tumor-reactive CD4+ T-cells reveals unexpected transcriptomic diversity 94%
- Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.